21/10/2014 | Press Releases
21st October 2014, Melbourne Australia
Specialty pharmaceutical company Hatchtech Pty Ltd today announced succesful completion of a Phase 2 clinical trial evaluating the ovicidal efficacy (ability to kill lice eggs) of a single 10 minute application of Xeglyze Lotion developed as a treatment for head lice infestation.
2/09/2014 | Press Releases
2nd September 2014 Melbourne, Australia
Specialty pharmaceutical company Hatchtech Pty Ltd today announced successful completion of its two pivotal Phase 3 clinical studies evaluating Xeglyze Lotion (formerly DeOvo Lotion) as a potential treatment for head lice infestation.
11/12/2013 | Press Releases
HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES AND STRENGTHENS PATENT PORTFOLIO
31/10/2013 | Press Releases
Hatchtech today announced the completion of a $12.6m capital raise to fund the Phase III clinical trial and NDA submission. The company also announced several changes to the composition of its Board.
13/03/2013 | Press Releases
Specialty pharmaceutical company Hatchtech Pty Ltd is pleased to announce the appointment of former Phosphagenics Vice President Mr Hugh Alsop as the company’s new Chief Executive Officer
13/12/2012 | Press Releases
Specialty pharmaceutical company Hatchtech Pty Ltd has completed a $6 million financing led by OneVentures Innovation Fund. This will enable the Company to commence the final stage of development of its novel head lice treatment product, DeOvo.
28/11/2012 | Press Releases
Specialty pharmaceutical company Hatchtech Pty Ltd has published data describing the mechanism of action of the active ingredient (Ha44) in its lead product DeOvo™, a single application topical treatment for head lice. The company also announced that it had successfully completed a Thorough QT (TQT) study, a clinical safety assessment required by US and European regulators for nearly all new molecular entities.
5/09/2012 | Press Releases
Specialty pharmaceutical company Hatchtech Pty Ltd announced today that it had successfully completed end-of-phase 2 (EOP2) consultations with the US Food & Drug Administration (FDA) for its lead product DeOvo™, a single application topical treatment for head lice.
25/07/2012 | Press Releases
Hatchtech Pty Ltd has been advised the United States Patent and Trademark Office has granted a patent covering a key element of the Company’s novel head lice treatment product, DeOvo™. In further progress, the Company’s Chief Scientific Officer Dr Vern Bowles has presented data from Hatchtech’s highly successful Phase 2b clinical trial at the recent 38th Annual Meeting of the Society for Pediatric Dermatology in the United States.
1/05/2012 | Press Releases
Hatchtech Pty Ltd has appointed Dr Ross Macdonald as its Chief Executive Officer. The company has also secured additional capital, bringing total funds raised in the current round to AUD7.8 million.
15/02/2012 | Press Releases
Hatchtech Pty Ltd is pleased to announce that it continues to secure global patent protection for its core DeOvo™ head lice treatment technology.
15/12/2011 | Press Releases
DeOvo™ demonstrates safety and clear efficacy against head lice and their eggs from one single application and is now positioned to accelerate into Phase 3.
31/08/2011 | Press Releases
Pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2 clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.
2/05/2011 | Press Releases
Venture-backed pharmaceutical company Hatchtech Pty Ltd has enrolled the first subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.
26/10/2010 | Press Releases
Venture-backed pharmaceutical company Hatchtech Pty Ltd has concluded a $6.3 million capital raising to conduct a Phase 2b clinical trial for its very promising head lice treatment.
1/08/2010 | Press Releases
Hatchtech Pty Ltd announced today that it had one of its key patents allowed in the United States. The patent protects Hatchtech’s lead compound for use in controlling a range of pests and parasites including head lice. ‘This patent represents a very important milestone for the company’ said Hatchtech’s founder and Chief Scientific Officer, Dr Vern Bowles. ‘The US is a key target market for our head lice product De Ovo™ he said.
No PDF Available
25/03/2010 | Press Releases
Hatchtech Pty Ltd confirms a successful Phase IIa clinical trial evaluating DeOvo™, an investigational proprietary drug being developed as a new topical treatment for head lice infestation.
28/11/2008 | Press Releases
Hatchtech Pty Ltd has secured $2.5 million in further funding from the University of Melbourne Endowment Trust (advised by GBS Venture Partners) and from Uniseed. The investment will be used to progress its unique head lice treatment into Phase II safety/efficacy studies in humans.
21/01/2008 | Press Releases
The US Food and Drug Administration (FDA) has accepted Hatchtech’s Investigational New Drug (IND) application allowing immediate commencement of Phase II clinical trials of the new ovicidal head lice treatment DeOvo™. These are multi-centre international trials and come after Hatchtech successfully completed DeOvo™ Phase I studies in Australia in 2007.
18/12/2007 | Press Releases
Anti-egg hatching technology company Hatchtech Pty Ltd has appointed Dr Stewart Washer as chairman of its board of directors. Dr Washer is best known for his past 15 years commercialising biotechnology and agribusiness technologies in Australia and New Zealand.
21/05/2007 | Press Releases
Hatchtech’s head louse control product has completed its first human trials finding no side effects or other adverse events associated with the product. 32 patients were treated at escalating dose levels and carefully monitored via observation, blood tests and electrocardiography. The trial was conducted by Q-Pharm in Queensland from February to April 2007.
23/01/2007 | Press Releases
Egg hatch control company Hatchtech Pty Ltd will commence development of a novel crop pest control product using a newly awarded $225,000 AusIndustry Commercial Ready Grant. The 12-month proof of concept project will commence this month to confirm product efficacy, mammalian safety and plant safety.
4/09/2006 | Press Releases
As Hatchtech’s core strength is a strong, sustainable pest control technology with
a growing focus on crop protection products, Mr Bunn’s substantial experience and expertise in this sector
will be invaluable in moving the Company forward and onto a commercial footing.
21/06/2006 | Press Releases
Melbourne based biotechnology company Hatchtech Pty Ltd was on Monday night honoured by winning two important prizes for commercialisation of technology that has enabled it to develop its world-leading lice control product.
15/05/2006 | Press Releases
Melbourne based biotechnology company Hatchtech Pty Ltd will proceed with full development of a lead head lice control candidate. The company will appoint a European laboratory to commence the pre-clinical and toxicity testing in readiness for the first human trials later this year.